Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
OKYO
Stock Latest News
The Fly
Okyo Pharma initiated with a Buy at Lucid Capital
1M ago
OKYO
Premium
Company Announcements
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
1M ago
6K
OKYO
Premium
The Fly
Okyo Pharma receives $1.9M in non-dilutive funding
1M ago
OKYO
Premium
Ratings
Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation
1M ago
OKYO
Premium
Company Announcements
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
2M ago
6K
OKYO
Premium
The Fly
Okyo Pharma reports Phase 2 clinical trial results for urcosimod
2M ago
OKYO
Premium
Company Announcements
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention
3M ago
6K
OKYO
Premium
Company Announcements
OKYO Pharma CEO to Present at Boston Drug Discovery Summit
3M ago
6K
OKYO
Premium
Company Announcements
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
4M ago
6K
OKYO
Premium
The Fly
Okyo Pharma announces FDA granted FTD to urcosimod
4M ago
OKYO
Premium
Ratings
Promising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target
4M ago
OKYO
Premium
Company Announcements
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain
4M ago
6K
OKYO
Premium
The Fly
Okyo Pharma announces plans to accelerate development of urcosimod
4M ago
OKYO
Premium
Company Announcements
OKYO Pharma Achieves Key Stability Milestone for Urcosimod
5M ago
6K
OKYO
Premium
The Fly
Okyo Pharma announces data on long-term stability of urcosimod
5M ago
OKYO
Premium
Company Announcements
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain
6M ago
6K
OKYO
Premium
The Fly
Okyo Pharma files for FTD with FDA for urcosimod
6M ago
OKYO
Premium
Ratings
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential
7M ago
OKYO
Premium
Company Announcements
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod
7M ago
6K
OKYO
Premium
The Fly
Okyo Pharma announces OK-101 officially assigned USAN, urcosimod
7M ago
OKYO
Premium
Ratings
Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges
7M ago
OKYO
Premium
Company Announcements
OKYO Pharma Executives Increase Shareholdings, Affirming Market Confidence
7M ago
6K
OKYO
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
